Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Real Life: One-Year Clinical and Economic Outcomes
| Autor: | Martine Roche, Romain Giraud, Manon Roche, Hervé Chambost, Céline Falaise, Nicolas Delmotte, Sophie Gensollen |
|---|---|
| Přispěvatelé: | Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Centre Régional de Traitement de l'Hémophilie, Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Assistance Publique - Hôpitaux de Marseille (APHM), Institut de Chimie Radicalaire (ICR), Aix Marseille Université (AMU)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS) |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Clotting factor
medicine.medical_specialty business.industry [SDV]Life Sciences [q-bio] 030226 pharmacology & pharmacy Recombinant factor viii 03 medical and health sciences Fc fusion Regimen 0302 clinical medicine Pharmacotherapy Internal medicine Weekly dose medicine In real life Pharmacology (medical) In patient 030212 general & internal medicine Original Research Article business |
| Zdroj: | Drugs-Real World Outcomes Drugs-Real World Outcomes, 2021, 8 (4), pp.527-535. ⟨10.1007/s40801-021-00259-2⟩ |
| ISSN: | 2198-9788 |
| DOI: | 10.1007/s40801-021-00259-2⟩ |
| Popis: | International audience; Background: Recombinant factor VIII Fc fusion protein (rFVIIIFc) is the first extended half-life (EHL) recombinant clotting factor with marketing authorization; it has been available in France since October 2016. However, data and literature about rFVIIIFc in clinical practice are scarce.Objective: We propose a 1-year clinical and economic outcome evaluation in patients with hemophilia A taking into consideration treatment adherence.Patients and methods: We reviewed the diaries of all patients treated with rFVIIIFc at Marseille Hemophilia Center for 1 year. All the data were related to the patients' infusion (i.e., annual number of infusions, weekly dose/kg, and annual consumption) and bleeding reports. The clotting factor costs were considered, whereas additional costs (e.g., infusion devices and nurse intervention) were neglected.Results: A total of 34 patients were evaluated. Their median age was 18 years (IQR = 18). Treatment adherence was observed in 62% for FVIII and 66% for rFVIIIFc. The analysis revealed a negligible decrease in the annual clotting factor consumption following the switch (- 2%, p = 0.7339). These data were combined with a significant reduction in the annual number of infusion (- 22.5%, median = 138.5, IQR = 65.8 for FVIII; median = 105, IQR = 24 for rFVIIIFc, p < 0.0001) and bleeding (- 50%, median = 5, IQR = 7.5 for FVIII; median = 1, IQR = 4 for rFVIIIFc, p < 0.0001). With regard to the cost, a decreasing trend was observed (- 8%, p = 0.1300).Conclusion: The analysis in a real-life setting revealed that the input of switches toward rFVIIIFc in different treatment (age of patients and regimen) patterns seems to corroborate previous studies. The results suggest that switches have a beneficial effect in terms of efficacy, clotting factor consumption, and cost. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink